863 1030
priorities could be explored. This approach represents an
effective way to collaboratively establish research priorities
with patients, caregivers, and health care providers.
Conflicts of interest:
The authors have nothing to disclose.
Acknowledgments:
The work was supported by a grant from the
Canadian Institutes of Health Research (grant 138851).
References
[1]
Caron-Flinterman JF, Broerse JE, Bunders JE. The experiential knowledge of patients: a new resource for biomedical research? Soc Sci Med 2005;60:2575–84.
[2]
Entwistle VA, Renfrew MJ, Yearley S, Forrester J, Lamont T. Lay perspectives: advantages for health research. BMJ 1998;316:463–6.
[3]
Goodare H, Lockwood S. Involving patients in clinical research improves the quality of research. BMJ 1999;319:724–5.[4] Canadian Institutes of Health Research. International Review Panel
report 2011.
www.cihr-irsc.gc.ca/e/43993.html.
[5] Canadian Institutes of Health Research. Canada’s strategy for pa-
tient-oriented research: improving health outcomes through evi-
dence-informed care. 2011.
www.cihr-irsc.gc.ca/e/44000.html.
[6] The James Lind Alliance.
www.jla.nihr.ac.uk .[7]
Cowan K, Oliver S. The James Lind Alliance guidebook: version 5. London, UK: The James Lind Alliance; 2013. p. 96.
[8] Patient-Centered Outcomes Research Institute. Easier treatment for
serious infection.
www.pcori.org .[9]
Stewart R, Oliver S. A systematic map of studies of patients’ and clinicians’ research. London, UK: The James Lind Alliance; 1998. p. 55.
[10] National Institute for Health Research. Patient and the public.
http://www.nihr.ac.uk/patients-and-public .[11]
Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal cell carcinoma: 2014 update. Eur Urol 2015;67:913–24.[12]
Novara G SS, Botteri M, De Marco V, Artibani W, Ficarra V. Factors predicting health-related quality of life recovery in patients under- going surgical treatment for renal tumors: prospective evaluation using the RAND SF-36 health survey. Eur Urol 2010;57:112–20.
[13]
Tallon D, Chard J, Dieppe P. Relation between agendas of the research community and the research consumer. Lancet 2000;355:2037–40.[14]
Ficarra V, Novella G, Sarti A, et al. Psycho-social well-being and general health status after surgical treatment for localized renal cell carcinoma. Int Urol Nephrol 2002;34:441–6.
[15]
Jones JM, Bhatt J, Avery J, et al. The kidney cancer research priority setting partnership: identifying the top ten research priorities as defined by patients, caregivers and expert clinicians. CUAJ 2017, in press.[16]
Armstrong AJ, Halabi S, Eisen T, et al. Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial. Lan- cet Oncol 2016;17:378–88.[17]
Tannira NM, Jonascha E, Albigesb L, et al. Everolimus versus suni- tinib prospective evaluation in metastatic non–clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial. Eur Urol 2016;69:866–74.
[18]
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 2016;374:135–45.[19]
Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet 2009;373:1119–32.[20]
Bhatt JR, Finelli A. Landmarks in the diagnosis and treatment of renal cell carcinoma. Nat Rev Urol 2014;11:517–25.[21]
Morrissey JJ, Mobley J, Figenshau RS, Vetter J, Bhayani S, Kharasch ED. Urine aquaporin 1 and perilipin 2 differentiate renal carcino- mas from other imaged renal masses and bladder and prostate cancer. Mayo Clin Proc 2015;90:35–42.[22]
Morrissey JJ, Mellnick VM, Luo J, et al. Evaluation of urine aqua- porin-1 and perilipin-2 concentrations as biomarkers to screen for renal cell carcinoma: a prospective cohort study. JAMA Oncol 2015;1:204–12.[23]
Franzen CA, Blackwell RH, Foreman KE, Kuo PC, Gupta GN. Urinary exosomes: the potential for biomarker utility, intercellular signal- ing, and therapeutics in urologic malignancy. J Urol 2016;195: 1331–9.[24]
Escudier B. Emerging immunotherapies for renal cell carcinoma. Ann Oncol 2012;23(Suppl 8):viii35–4.
[25]
Thomas JS, Kabbinavar F. Metastatic clear cell renal cell carcinoma: a review of current therapies and novel immunotherapies. Crit Rev Oncol Hematol 2015;96:527–33.
[26]
Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med 2015;373:1803–13.[27]
Tomaszewski JJ, Uzzo RG, Smaldone MC. Heterogeneity and renal mass biopsy: a review of its role and reliability. Cancer Biol Med 2014;11:162–72.
[28]
Sankin A, Hakimi AA, Mikkilineni N, et al. The impact of genetic heterogeneity on biomarker development in kidney cancer assessed by multiregional sampling. Cancer Med 2014;3: 1485–92.
[29]
Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014;46:225–33.[30]
Kwiatkowski DJ, Choueiri TK, Fay AP, et al. Mutations in TSC1, TSC2, and MTOR are associated with response to rapalogs in patients with metastatic renal cell carcinoma. Clin Cancer Res 2016;22:2445–52.[31]
Sonpavde G, Choueiri TK. Precision medicine for metastatic renal cell carcinoma. Urol Oncol 2014;32:5–15.[32]
Voss MH, Chen D, Marker M, et al. Circulating biomarkers and outcomes from a randomised phase II trial of sunitinib vs ever- olimus for patients with metastatic renal cell carcinoma. Br J Cancer 2016;114:642–9.
[33]
Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015;14:847–56.[34]
De P, Otterstatter MC, Semenciw R, Ellison LF, Marrett LD, Dryer D. Trends in incidence, mortality, and survival for kidney cancer in Canada, 1986-2007. Cancer Causes Control 2014;25:1271–81.[35]
Anastasiadis AG, Davis AR, Sawczuk IS, et al. Quality of life aspects in kidney cancer patients: data from a national registry. Support Care Cancer 2003;11:700–6.
[36]
Moretto P, Jewett MAS, Basiuk J, Maskens D, Canil CM. Kidney cancer survivorship survey of urologists and survivors: the gap in perceptions of care, but agreement on need. Can Urol Assoc J 2014;8:190–4.[37]
Cancer Journey Survivorship Expert Panel. Survivorship services for adult cancer populations: a pan-Canadian guideline. Curr Oncol 2011;18:e265–81.
[38]
Stacey D, Le´gare´ F, Col NF, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2014;2014:CD001431.[39] The Ottowa Hospital Research Institute. Patient Decision Aids
Research Group. A to Z inventory of decision aids.
https:// decisionaid.ohri.ca/azlist.html .[40]
Elwyn G, Scholl I, Tietbohl C, et al. ‘‘Many miles to go ..
. ’’: a systematic review of the implementation of patient decision support interventions into routine clinical practice. BMC Med Informat Decision Making 2013;13(Suppl 2):S14.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 8 6 1 – 8 6 4
863